secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001437749-26-004246
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharma announces FDA path to NDA for NRX-100 with broader TRD+suicidality indication
--------------------------------------------------------------------------------

- FDA meeting provided clear path to submit NDA for NRX-100 under Fast Track; endpoints support full approval rather than Accelerated Approval.
- Indication expanded to treatment-resistant depression with suicidality, targeting over 10 million TRD patients.
- Real World Evidence from 65,000+ patient dataset to be used as confirmatory data; FDA to review analysis protocol.
- NDA submission planned for Q2 2026; PDUFA date anticipated in 2026.
- ANDA for generic ketamine remains under review with decision expected Summer 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926004246/0001437749-26-004246-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926004246/nrxp20260216c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-004246

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer